Search results
Earnings call: Enanta Pharmaceuticals Q2 fiscal results and pipeline updates By Investing.com
Investing.com· 6 hours agoEnanta Pharmaceuticals (NASDAQ: NASDAQ:ENTA), a biopharmaceutical company focused on developing oral...
Healthy Returns: Sales of Humira are plunging, but AbbVie has two promising successors
CNBC· 6 days agoSales of AbbVie's Humira are plummeting as the once-top-selling drug fights competition from cheaper...
Decoding AbbVie Inc (ABBV): A Strategic SWOT Insight
GuruFocus.com via Yahoo Finance· 4 days agoAdditionally, AbbVie faces external threats from regulatory challenges and intellectual property disputes. By leveraging its strengths and addressing its...
Teva Earnings Are Soon. What Could Keep the Stock Gains Going.
Barrons.com· 3 hours agoShares of Teva Pharmaceutical Industries have done something unusual this year: They’ve gone up. The...
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
Zacks via Yahoo Finance· 6 days agoShares of this drugmaker have returned -10% over the past month versus the Zacks S&P 500 composite's...
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
InvestorPlace· 5 hours agoInvestors concerned about broader market undulations may want to consider the resilience narrative...
Enanta Pharmaceuticals Reports Fiscal Q2 Results: A Closer Look
Guru Focus· 1 day agoOn May 6, 2024, Enanta Pharmaceuticals Inc (ENTA, Financial), a pioneering biotechnology firm focused on developing treatments for viral infections and liver diseases...but ...
In re Cellect Poses an Obvious Dilemma | JD Supra
JD Supra· 16 hours agoIn August 2023, the Federal Circuit in In re Cellect held that in evaluating unpatentability for obviousness-type double patenting (ODP) of a patent...
AbbVie (NYSE:ABBV) Price Target Cut to $187.00
ETF DAILY NEWS· 6 days agoAbbVie (NYSE:ABBV – Get Free Report) had its target price cut by equities researchers at Barclays from $195.00 to $187.00 in a research report issued on Monday, Benzinga reports ...
The top pharmaceutical companies by R&D expenditure
Pharmaceutical Technology via Yahoo Finance· 6 days agoLast year, major pharmaceutical companies heavily invested in R&D, with expenditure ranging from around 14% to 50% of their revenues. Some of the...
